15-甲基十六烷酸 | 1603-03-8

• 物质功能分类: 分析化学 - 食品安全 - 脂肪酸、脂肪酸甲酯
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 15-甲基十六烷酸
• 英文名称: isomargaric acid
• 英文别名: 15-methylhexadecanoic acid；15-methylpalmitic acid；15-Methyl-hexadecansaeure
• CAS: 1603-03-8
• 化学式: C₁₇H₃₄O₂
• mdl: MFCD00083427
• 分子量: 270.456
• InChiKey: IIUXHTGBZYEGHI-UHFFFAOYSA-N

物化性质

• 熔点：
  59.5-60 °C
• 沸点：
  358.05°C (estimate)
• 密度：
  0.8791 (rough estimate)
• 溶解度：
  氯仿：可溶；乙醇：可溶；乙醚：可溶
• LogP：
  7.500 (est)
• 保留指数：
  2980
• 稳定性/保质期：

  存在于烤烟烟叶中。

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  19
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.941
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2915900090
• 储存条件：
  2-8°C

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 15-Methylpalmitic acid
CAS-No. : 1603-03-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Safety data sheet available on request.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 15-Methylhexadecanoic acid
Formula : C17H34O2
Molecular Weight : 270,45 g/mol
Component Concentration
15-Methylhexadecanoic acid
CAS-No. 1603-03-8 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

1. 烟草: FC, 15。

合成制备方法

1. 烟草: FC, 15。

用途简介

暂无相关信息。

反应信息

• 作为反应物：
  描述：

  15-甲基十六烷酸 在 lithium aluminium tetrahydride 、 乙醚 、 硫酸 、 甲苯 作用下， 生成 15-methyl-1-hexadecanol
  参考文献：
  名称：

  Weitzel; Wojahn, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1951, vol. 287, p. 296,304,305

  摘要：

  DOI：
• 作为产物：
  描述：

  15-methylhexadecan-1,15-diol 在 三乙基硅烷 、 potassium permanganate 、 三氟化硼乙醚 、 四丁基溴化铵 、 溶剂黄146 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 24.75h， 生成 15-甲基十六烷酸
  参考文献：
  名称：

  长链异脂肪酸 (iso-C12-C19) 和相关天然产物的实用合成。

  摘要：

  从十一碳烯酸甲酯（十一碳烯酸甲酯）（对于异 C12-C14）或 C15 和 C16 内酯十五烷内酯开始，开发了末端支化异脂肪酸（iso-C12-C19）的克级合成（异-C15-C17）和十六烷内酯（异-C18-C19）。概述的方法的核心是通过将甲基溴化镁添加到酯/内酯和选择性还原所得叔醇来两步构建末端异丙基。因此，C12、C17 和 C18 异脂肪酸是从市售原料中分三步获得的，其余的 C13-C16 和 C19 异脂肪酸通过这些脂肪酸的同系或递归脱同系或通过拦截来制备合适的中间体。

  DOI：

  10.3762/bjoc.9.210

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• Mycobacterium tuberculosis β-gentiobiosyl diacylglycerides signal through the pattern recognition receptor Mincle: total synthesis and structure activity relationships
  作者：Mark B. Richardson、Shota Torigoe、Sho Yamasaki、Spencer J. Williams

  DOI：10.1039/c5cc04773k

  日期：——

  Gentiobiosyl diglycerides fromMycobacterium tuberculosisare shown to signal through Mincle; structure–activity relationships reveal analogues with enhanced potency.

  结核分枝杆菌中的甘露二糖基二甘油酸被证明通过Mincle信号传导；结构-活性关系揭示出具有增强效力的类似物。
• Synthesis and biological activity of phosphoglycolipids from Thermus thermophilus
  作者：Yukari Fujimoto、Kunihiro Mitsunobe、Satoko Fujiwara、Motoko Mori、Masahiro Hashimoto、Yasuo Suda、Shoichi Kusumoto、Koichi Fukase

  DOI：10.1039/c3ob40899j

  日期：——

  opposite configuration at the diacyl glycerol moiety, were also synthesized. The biological activities of the synthesized compounds were elucidated with cytokine inductions (IL-6 and TNF-α). A synthetic phosphoglycolipid with a natural-type diacyl glycerol configuration showed apparent immunostimulatory activity, whereas its diastereomer did not. The present study revealed that the configuration at the

  极端嗜热菌Thermus thermophilus在细胞表面具有非常独特的糖脂。嗜热链球菌的酸性免疫刺激性磷酸糖脂首次使用新开发的糖基化方法，使用3-硝基吡啶基（3NPy）和4,6-二甲氧基-1,3,5-三嗪-2-基（DMT）糖苷作为糖基供体进行合成。还合成了磷酸糖脂的类似物，其包括在二酰基甘油部分具有相反构型的非对映异构体。通过细胞因子诱导（IL-6和TNF-α）阐明了合成化合物的生物学活性。具有天然型二酰基甘油构型的合成磷酸糖脂显示出明显的免疫刺激活性，而其非对映异构体则没有。本研究表明，磷酸糖脂的二酰基甘油部分的构型对于免疫刺激很重要，
• COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID
  申请人：ADOCIA

  公开号：US20190275108A1

  公开（公告）日：2019-09-12

  A composition in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, including at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy being according to formula I below: *GpR r GpA a GpC) p Formula I wherein the composition does not comprise a basal insulin the isoelectric point pI of which is comprised from 5.8 to 8.5. It also relates to a composition wherein it further includes prandial insulin.

  一种以可注射的水溶液形式的组合物，其pH值为6.0至8.0，包括至少：a) 胰淀粉样素、胰淀粉样素受体激动剂或胰淀粉样素类似物；b) 载有羧基电荷和疏水基团Hy的共聚氨基酸，所述共聚氨基酸由谷氨酸或天冬氨酸单元构成，所述疏水基团Hy按照下面的公式I：*GpRrGpAaGpC)p。其中，该组合物不包括等电点pI为5.8至8.5的基础胰岛素。还涉及一种组合物，其中还包括餐后胰岛素。